Monitoring and Controlling Biocatalytic Processes
by John Woodley and Paul A. Bird, the Advanced Centre for Biochemical Engineering at University College, London, and David C.A. Sharp, Pfizer Global R&D. Increased selectivity and byproduct prevention are some of the advantages of using biocatalytic processes for manufacturing chiral products and chemical intermediates. yet no industrial processes are currently using biocatalysts with Baeyer?Villiger monooxygenases because, among other factors, available monitoring and control techniques have not been rapid enough to prevent reactant and product inhibition. However, as the authors describe, rapid monitoring and control can now be achieved using near-infrared spectroscopy that, during tests, resulted in a 30% gain in productivity.
Mastering Antibody-Drug Conjugates
December 19th 2024In this episode, we explore BIOVECTRA’s capabilities in antibody-drug conjugate (ADC) manufacturing, from complex conjugation chemistry to synthesis of highly potent payloads. We’ll also showcase how BIOVECTRA’s extensive experience in complex chemistries and specialized small molecule manufacturing gives them a unique perspective, strengthening their approach to ADC production and ensuring clients receive custom solutions across all project stages.
